Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†


1Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany; 2Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; 3Department of Medicine, Royal Marsden Hospital, Surrey, UK; 4Direttore Dipartimento di Oncologia e U.O.C. Oncologia Medica A.O., Benevento, Italy; 5Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, Mount Sinai Liver Cancer Program, New York, USA; 6Barcelona-Clinic Liver Cancer Group (BCLC), Unitat d’Hepatologia, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Universitat de Barcelona, Barcelona, 7Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; 8Oncology, Royal Free Hospital, London; 9UCL Cancer Institute, University College London, London, UK; 10Service d’hépatologie, Hôpital Jean Verdier, Bondy, France; 11Klinik für Allgemeinen- und Viszeralchirurgie, Medizinische Fakultät der RWTH Aachen; 12Klinik und Poliklinik für Radiologie, Ludwig-Maximilians-Universität München, Munich, Germany; 13Liver Unit, Clinica Universidad de Navarra-IDISNA and CIBERehd, Pamplona, Spain; 14Institute of Pathology, University Hospital, Heidelberg, Germany; 15Campus Gasthuisberg, UZ Leuven, Leuven, Belgium; 16Klinik für Radiologie und Nuklearmedizin Universität Basel, Basel, Switzerland; 17Department Oncology, Section Hematology and Palliative Care AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany; 18Faculty of Medicine, Università della Campania L. Vanvitelli Naples, Caserta, Italy

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org
†Approved by the ESMO Guidelines Committee: August 2018.

Incidence and epidemiology

The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last 20 years and is expected to increase until 2030 in some countries including the United States, while in other countries, such as Japan, the incidence has started to decline [1–3]. In 2012, liver cancer represented the fifth most common cancer in men (554 000 new cases) and the ninth in women (228 000 new cases) and the second most common cause of cancer-related death (746 000 estimated deaths), worldwide [3]. The incidence varies from 3/100 000 in Western countries, to 78.1/100 000 in Mongolia, with the highest incidence in Africa and Asia, mapping the geographical distribution of viral hepatitis B (HBV) and hepatitis C (HCV), the most important causes of chronic liver disease and HCC [4]. In Europe, in 2012 the estimated incidence rate was 10.0 in men and 3.3 in women per 100 000, respectively, while the estimated mortality rate was 9.1 and 3.3 per 100 000 in men and women, respectively [3]. The incidence of HCC shows a strong male preponderance and increases progressively with advancing age in all populations. The association of chronic liver disease and HCC represents the basis for preventive strategies, including universal vaccination at birth against HBV [I, A] [5] and early antiviral treatment of viral HBC and HCV [III, A] [6–8]. The prevalence of obesity and type 2 diabetes has greatly increased in the past decades, leading to a rising incidence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which can lead to fibrosis and cirrhosis and, eventually, HCC [9]. HCC related to NAFLD/NASH is probably underestimated [10] and is expected to rise in the future, possibly overtaking the other aetiologies in some areas of the world [11]. A significant proportion of patients with NAFLD/NASH-associated HCC do not have histological evidence of cirrhosis [12].

The control of other risk factors for chronic liver disease and cancer is more difficult to implement, such as cutting down on the consumption of alcohol and programmes aiming at a healthier lifestyle in the light of the obesity pandemic [13, 14]. In Africa, reduction of exposure to aflatoxin B1, especially in HBV-infected individuals, may lower the risk of HCC. HCC may evolve from reduction of exposure to aflatoxin B1, especially in HBV-infected individuals, respectively [3]. The incidence of HCC shows a strong male preponderance and increases progressively with advancing age in all populations. The association of chronic liver disease and HCC represents the basis for preventive strategies, including universal vaccination at birth against HBV [I, A] [5] and early antiviral treatment of viral HBC and HCV [III, A] [6–8]. The prevalence of obesity and type 2 diabetes has greatly increased in the past decades, leading to a rising incidence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which can lead to fibrosis and cirrhosis and, eventually, HCC [9]. HCC related to NAFLD/NASH is probably underestimated [10] and is expected to rise in the future, possibly overtaking the other aetiologies in some areas of the world [11]. A significant proportion of patients with NAFLD/NASH-associated HCC do not have histological evidence of cirrhosis [12].

Surveillance

Surveillance of HCC involves the repeated application of screening tools in patients at risk for HCC and aims for the reduction in mortality of this patient population. The success of surveillance is influenced by the incidence of HCC in the target population, the availability and acceptance of efficient diagnostic tests and the
availability of effective treatment. Cost-effectiveness studies suggest surveillance of HCC is warranted in all cirrhotic patients irrespective of its aetiology [15], as long as liver function and comorbidities allow curative or palliative treatments [III, A]. Surveillance of non-cirrhotic, hepatitis-infected patients should also be considered in chronic HBV carriers or HCV-infected patients with bridging fibrosis (F3, numerous septa without cirrhosis) [III, A], which are at higher risk than the general population. Specifically in Asian patients, serum HBV-DNA above 10,000 copies/mL was associated with a higher annual risk (above 0.2%/year) compared with patients with a lower viral load [16].

Patients with HCV infection and advanced fibrosis remain at increased risk for HCC even after achieving sustained virological response following antiviral treatment [III, A] [8] and, thus, should remain in a surveillance programme. Japanese cohort studies have shown that surveillance by abdominal ultrasound (US) resulted in an average size of the detected tumours of 1.6 ± 0.6 cm, with < 2% of the cases exceeding 3 cm [17]. In the Western world and in less experienced centres, the sensitivity of finding early-stage HCC by US is considerably less effective [18]. There are no data to support the use of contrast-enhanced computed tomography (CECT) or contrast-enhanced magnetic resonance imaging (CEMRI) for surveillance. Adding the determination of serum alpha foetoprotein (AFP) to US can lead to a 6% gain in the early HCC detection rate, but at the price of false-positive results and of a worse cost-effectiveness ratio [19]. A randomised controlled trial (RCT) of Chinese patients with chronic HBV infection compared surveillance (US and serum AFP measurements every 6 months) versus no surveillance [20]. Despite low compliance with the surveillance program (55%), HCC-related mortality was reduced by 37% in the surveillance arm. Considering the most appropriate surveillance interval, a randomised study comparing a 3- versus 6-month schedule failed to detect any differences [21]. Surveillance of patients at risk for HCC should be carried out by abdominal US every 6 months with or without AFP [II, A].

**Diagnosis and pathology/molecular biology**

The diagnosis of HCC is based on histological analysis and/or contrast-enhanced imaging findings [III, A]. The diagnostic work-up of a patient with an HCC-suspicious nodule is given in Table 1.

**Diagnosis by imaging**

In patients with liver cirrhosis and specific imaging criteria, a formal pathological proof is not mandatory for diagnosis and the clinician can rely on the contrast-enhanced imaging criteria for lesion characterisation [22–24]. These criteria require a multiphasic CECT or CEMRI. The diagnosis can be established if the typical vascular hallmarks of HCC (hypervascularity in the arterial phase with washout in the portal venous or delayed phase) are identified in a nodule of > 1 cm diameter using one of these two...
modalities [III, A]. Compared with multiple detector CT (MDCT), multiphasic MRI offers a moderate increase in sensitivity for diagnosing HCC based on the typical vascular hallmarks [III, B] [24–27]. Serum AFP has no role in the diagnostic algorithm [III, A].

Based on techniques such as diffusion-weighted imaging and the use of hepatobiliary contrast agents, MRI may identify and stratify nodules as high-risk nodules (either HCC not displaying the typical imaging hallmarks features or high-grade dysplastic nodules) [IV, B] [28–31]. However, the impact of identification of additional nodules by diffusion-weighted imaging and hepatobiliary contrast agents on the therapeutic algorithm remains unclear and switching to palliative treatments after identification of potential premalignant nodules by these new techniques should be avoided. New imaging criteria for HCC diagnosis called CT/MRI LI-RADS® V2018 (Liver Imaging Reporting and Data System) include arterial phase enhancement, tumour size, washout, enhancing capsule and threshold growth and have been proposed to improve the diagnosis of HCC, especially for small nodules (Table 2) [32, 33].

Angiography and fluorodeoxyglucose-positron emission tomography (FDG-PET) scan are not recommended for HCC diagnosis. When tumour biopsy fails to demonstrate a correlate for a focal lesion, a second tumour biopsy, a different contrast-enhanced imaging modality or (if amenable) direct resection of the lesion may be considered according to tumour size [IV, B]. If the patient is a candidate for resection that can be carried out with an acceptable morbidity and mortality risk, then either biopsy or direct resection may be an option.

### Diagnosis by pathology

Pathological diagnosis of HCC is based on a biopsy or a surgical specimen of the tumour. Concomitant analysis of the non-tumour liver may be useful in order to define its status and potential causative diseases. Assessment of resection and explant specimens follows the valid TNM (tumour, node, metastasis) classification including resection margin evaluation. Usually tumour grade is provided, but currently no uniform grading scheme is used worldwide and data on the independent prognostic value are inconclusive.

Histopathological diagnosis of tumour biopsies relies on standard [e.g. haematoxylin and eosin (H&E)] and special stains (e.g. reticulin), and—if required—immunohistochemistry (IHC). It should address different challenges: morphologically, highly differentiated HCC must be distinguished from benign/premalignant lesions (dysplastic nodules, hepatocellular adenoma, focal nodular hyperplasia). In particular, poorly differentiated HCC should be distinguished from intrahepatic CC,

---

**Table 2. CT/MRI LI-RADS diagnostic table**

<table>
<thead>
<tr>
<th>Untreated observation without pathological proof in patient at high risk for HCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitely benign: LR-1</td>
</tr>
<tr>
<td>Probably benign: LR-2</td>
</tr>
<tr>
<td>Not categorisable, due to image degradation or omission: LR-NC</td>
</tr>
<tr>
<td>Define tumour in vein (TIV): LR-TIV</td>
</tr>
<tr>
<td>Probably or definitely malignant but not HCC specific (e.g. if targetroid): LR-M</td>
</tr>
</tbody>
</table>

**Otherwise, use CT/MRI diagnostic table below**

Intermediate probability of malignancy: LR-3

Probably HCC: LR-4

Definitely HCC: LR-5

<table>
<thead>
<tr>
<th>Arterial phase hyperenhancement (APHE)</th>
<th>No APHE</th>
<th>APHE (not rim)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation size (mm)</td>
<td>&lt; 20</td>
<td>≥ 20</td>
</tr>
<tr>
<td>Count major features: None</td>
<td>LR-3</td>
<td>LR-3</td>
</tr>
<tr>
<td>‘Washout’ (not peripheral) One</td>
<td>LR-3</td>
<td>LR-4</td>
</tr>
<tr>
<td>Enhancing ‘capsule’ ≥ Two</td>
<td>LR-4</td>
<td>LR-4</td>
</tr>
</tbody>
</table>

**Threshold growth**

<table>
<thead>
<tr>
<th>LR-3</th>
<th>LR-4</th>
<th>LR-5</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>LR-3</td>
<td>LR-4</td>
</tr>
<tr>
<td>One</td>
<td>LR-3</td>
<td>LR-4</td>
</tr>
<tr>
<td>≥ Two</td>
<td>LR-4</td>
<td>LR-4</td>
</tr>
</tbody>
</table>

**Threshold growth definition:**

- ≥ 50% increase in size in ≤ 6 months, OR
- Previously unseen on CT or MRI, now ≥ 10 mm, in ≤ 24 months.

**Observations in this cell are categorised based on one additional major feature:** LR-4 if enhancing ‘capsule’; LR-5 if non-peripheral ‘washout’ OR threshold growth.

CT, computed tomography; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting and Data System; LR, liver resection; MRI, magnetic resonance imaging.
combined HCC/CC and some types of metastases (e.g. lung cancer, head and neck squamous cell carcinoma, breast cancer, neuroendocrine tumours). For this reason, histological analyses may be supplemented by IHC for lineage-specific markers. It is important to distinguish combined HCC/CC from HCC due to the different therapeutic modalities; however, the mixed differentiation features might not be visible in the biopsy. In addition, significant expression of cytokeratin 19 (CK19) has been evaluated and considered as a sign of poor prognosis in HCC [IV, B].

In highly differentiated HCC, definitive signs of malignancy (interstitial or vascular invasion) are frequently absent from biopsy. Further consented histological (trabecular alterations—more than two cell broad trabeculae, pseudoglands, reticulin loss, capsule formation) and cytological criteria (increased nuclear/cytoplasmic ratio, i.e. ‘nuclear crowding’, increased cytoplasmic basophilia) support HCC diagnosis [III, B] [37]. IHC should be carried out in unclear cases: capillarisation of sinusoids could be assessed using CD34 IHC [IV, B] [37]. Further immunohistochemical markers have been shown to improve the diagnosis of highly differentiated HCC, including glutamine synthetase, glypican 3, general stress protein (CTC), enhancer of zeste homologue 2 (EZH2) and heat shock protein 70 (HSP70) [IV, B]. A combination of the three markers glutamine synthetase, glypican 3 and HSP70 has been consented as a diagnostic panel (2/3 marker positivity has 70% sensitivity and 100% specificity for HCC) and the use of further markers seems to increase the sensitivity [IV, B] [38]. Moreover, histological subtypes of HCC have been defined (e.g. fibrolamellar, chromophobe, macrotabecular massive) which specifically correlate with clinical and molecular features [39, 40], which may have future clinical impact.

It is now well accepted that the potential risks of tumour biopsy, bleeding and needle track seeding, are infrequent, manageable and do not affect the course of the disease or overall survival (OS) and, therefore, should not be seen as a reason to abstain from diagnostic liver biopsy. In a comprehensive meta-analysis, the risk of tumour seeding after liver biopsy was reported to be 2.7%, with a median time interval between biopsy and seeding of 17 months [41], but even lower rates are expected in experienced centres. It was reported that needle track seeding can be treated well (e.g. by excision or radiation) and did not affect outcome of oncological treatment [42] and OS [41]. In a meta-analysis of the bleeding risk, mild bleeding complications ranged around 3–4%, while severe bleeding complications, requiring transfusions, were reported in 0.5% of the cases [43].

**Staging and risk assessment**

Staging of HCC is important to determine outcome and planning of optimal therapy and includes assessment of tumour extent, AFP level, liver function, portal pressure and clinical performance status (PS) (Table 1) [III, A]. Relevant techniques to evaluate tumour extent (number and size of nodules, vascular invasion, extrahepatic spread) include CEMRI or helical CT. CT of the chest, abdomen and pelvis is recommended to rule out extrahepatic spread. There is no justification for routine preoperative bone scintigraphy to detect asymptomatic skeletal metastases in patients with resectable HCC [44] and there are no data in the context of advanced HCC. There is no demonstrated clinical benefit of carrying out FDG-PET scan as a staging modality, despite some evidence that there is a correlation of higher FDG uptake with poor differentiation, tumour size, serum AFP levels and microvascular invasion [IV, D] [45, 46].

Liver function is classically assessed by the Child-Pugh scoring system (serum bilirubin, serum albumin, ascites, prothrombin time and hepatic encephalopathy) [III, A]. Within the Child-Pugh A group, measurement of the albumin-bilirubin (ALBI) score (a model incorporating serum albumin and bilirubin levels alone) is able to split that group into good prognosis (ALBI 1) and poor prognosis (ALBI 2), with median survivals of 26 versus 14 months, respectively [IV, B] [47]. A platelet count > 150 x 10⁹ cells/L and a non-invasive liver stiffness measurement < 20 kPa excludes clinically significant portal hypertension (Baveno VI criteria) [48]. Otherwise, the finding of oesophageal varices and/or splenomegaly with blood platelet counts of 100 x 10⁹ cells/L suggests clinically important portal hypertension, which can also be measured invasively by the transjugular route (hepatic-venous pressure gradient > 10 mmHg) [III, A].

Several staging systems—incorporating some or all of the above-mentioned items—have been developed, including TNM, Okuda, Cancer of the Liver Italian Program (CLIP), Japanese Integrated Staging (JIS) Score and the Barcelona Clinic Liver Cancer (BCLC) system. Every system has advantages and drawbacks. The recently released 8th edition of the TNM system (Table 3) contains changes to the T classifications compared with the previous staging system [49]. The staging system includes microvascular invasion that can only be assessed on pathology and is therefore less useful in clinical practice before treatment decision making. Moreover, a recent validation study pointed to potential problems of heterogeneity in the T2 category and the lack of vascular invasion as a prognostic factor in the T3 group [50]. TNM classification provides a means of standardising histopathological reports in patients treated by resection or transplantation.

The BCLC staging system was developed on the basis of the results of RCTs and cohort studies and links tumour stage, liver function, cancer-related symptoms and PS to an evidence-based treatment algorithm (Table 4). The system identifies those patients with early HCC who may benefit from ablative treatment (stage 0 and A), those at intermediate (stage B) or advanced stage (stage C) who may benefit from intra-arterial or systemic treatments and those with a very poor life expectancy (stage D). Survival without therapy is > 5 years for stage 0 and A, > 2.5 years for stage B, > 1 year for stage C and ~3 months for stage D [51]. Treatment assignment of the different stages is discussed below. The aetiology of co-existent liver disease has not been identified as an independent prognostic factor. Nevertheless, finding a treatable underlying co-existent liver disease may be very relevant, e.g. antiviral treatment in case of HBV, corticosteroid treatment in autoimmune hepatitis or stopping alcohol intake may result in a marked improvement in liver function and improving prognosis.

Liver decompensation (including jaundice, variceal haemorrhage, ascites or encephalopathy) should be considered a contraindication for any locoregional therapy that may induce subclinical liver damage such as resection, percutaneous ablation or transarterial therapies. The benefit of systemic therapies has not been established in patients with liver decompensation.
Management of early and intermediate HCC

Liver resection (LR), orthotopic liver transplantation (OLT) and local destruction methods [radiofrequency ablation (RFA) or microwave ablation (MWA)] comprise potentially curative treatment modalities for patients with HCC (see Figure 1). Selecting the appropriate treatment for the individual patient remains difficult and there are no randomised phase III trials comparing the efficacy of these three approaches; all evidence is based on cure rates in patient series.

The predominant arterial vascularisation of HCC resulted in the application of intra-arterial administration of chemotherapy (e.g. doxorubicin, cisplatin), embolising material (e.g. coils, gelatin sponge particles) or radioactive particles. These therapies are generally regarded as palliative treatment options but may provide complete tumour destruction in well-selected candidates.

Liver resection

Single tumours in patients with well-preserved liver function is the mainstay indication for resection, provided a R0 resection (excision whose margins are clear of tumour cells) can be carried out without causing postoperative liver failure due to insufficient reserve in the liver remnant. LR requires a detailed preoperative work-up with the assessment of liver function and future liver remnant volume. The combination of both variables determines the perioperative risk of liver failure and the associated complications. Child-Pugh A patients without significant portal hypertension are considered good candidates for minor/major LRs [III, B]. Child-Pugh C patients are not suitable for surgical therapy. A recent meta-analysis demonstrates that the presence of portal hypertension or Child-Pugh B status might not be an absolute contraindication and provide acceptable results for these cohorts [52, 53]. Therefore, carefully selected patients with Child-Pugh B and/or portal hypertension may be candidates for minor surgical resection [III, A].

Compared with open LR, laparoscopic LR results in reduced intraoperative blood loss, faster postoperative recovery and does not impair oncological outcome [54]. LR in cirrhosis should preferably be carried out as laparoscopic resection [IV, A]. Currently, there is no high-level evidence to recommend surgical resection in cirrhotic HCC patients with advanced tumour burden and macrovascular invasion.

After LR, tumour recurrence can be observed in 50%–70% of cases within 5 years following surgery, which constitutes either intrahepatic metastases (often within 2 years following surgery) or a new HCC in the remaining cirrhotic liver (occurring more often beyond 2 years). Even though the vast majority of HCC recurrences occur within the liver as a result of subclinical micro-metastases and vascular invasion from the primary tumour, the extent of surgical resection [anatomical resection (AR) versus non-anatomical wedge resection (NAR)] is still a subject of ongoing debate. Theoretically, the systematic removal of the hepatic segment through an AR is considered to be more effective in terms of tumour clearance and eradication of micro-metastases [55]. This, however, is rarely possible in cirrhotic HCC patients for whom tissue-sparing NAR is the procedure of choice to...
reduce the risk of post-operative liver failure [56]. While some groups report superiority of AR, overall conflicting results are reported, and no clear recommendation may be given due to a lack of currently available high-level clinical evidence [57, 58].

**Orthotopic liver transplantation**

Liver transplantation offers the possibility to cure both the tumour and the underlying liver disease [59]. The Milan criteria (one lesion < 5 cm; alternatively, up to three lesions, each < 3 cm; no extrahepatic manifestations; no evidence of macrovascular invasion) are currently the benchmark for the selection of patients with HCC for OLT. OLT is recommended for patients that fit the Milan criteria, for which < 10% recurrence and 70% 5-year survival are expected [II, A] [60]. Among several more liberal proposals [up-to-seven criteria, extended Toronto criteria, University of California San Francisco (UCSF) criteria], only the UCSF criteria (one tumour < 6.5 cm, three nodules at most with the largest ≤ 4.5 cm and total tumour diameter ≤ 8 cm) were prospectively validated and showed similar outcome and, as such, may also be considered for OLT in patients with HCC beyond Milan criteria [III, B] [60, 61]. The use of marginal grafts or living donor liver transplantation could facilitate the treatment of these patients [62–64].

The low availability of liver allografts, however, is a major limitation for OLT, and liver transplant candidates are often confronted with long waiting times, which may be associated with tumour progression beyond the Milan criteria. When a waiting time (> 3 months) is anticipated, patients may be offered resection, local ablation or transarterial chemoembolisation (TACE) in order to minimise the risk of tumour progression and to offer a ‘bridge’ to transplant [III, B].

**Adjuvant therapies**

Adjuvant therapy is not recommended for HCC patients after OLT, LR or local ablation [I, E]. Mammalian target of rapamycin (mTOR) inhibitors are used as immunosuppressant to prevent graft rejection in liver transplantation (sirolimus) but have failed to improve recurrence-free survival in a recently published phase III study [65]. Similarly, sorafenib did not improve median recurrence-free survival of HCC patients after LR or local ablation [66].

**Thermal tumour ablation**

Thermal ablation by RFA or MWA may be recommended as first-line treatment in very early-stage disease (BCLC 0) [II, A]. In
**Figure 1.** HCC treatment options depending on BCLC stage.

- See Table 4 for indication constraints based on tumour burden and liver function.
- Not EMA-approved as of August 2018.

BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care; EMA, European Medicines Agency; HCC, hepatocellular carcinoma; LTX, liver transplantation; SBRT, stereotactic body radiotherapy; SIRT, selective internal radiotherapy; TACE, transarterial chemoembolisation.
very early-stage disease (tumours < 2 cm diameter), RFA has demonstrated similar outcomes to LR and thus may be recommended as first-line treatment, specifically in light of its lesser invasiveness and morbidity compared with surgery [64]. In patients with early-stage HCC (up to three lesions ≤ 3 cm), RFA has been adopted as an alternative first-line option irrespective of liver function after demonstrating survival benefit similar to surgery in RCTs and meta-analyses [64, 67–70]. To date, MWA has not been adequately tested in comparison to RFA and the potential advantage for tumours between 3 and 5 cm or the reduced impact of the cooling effect of adjacent large vessels remains unknown. Both methods have limitations in exophytic tumours as well as those close to the gallbladder, liver hilum or with neighbouring intestine, which may be overcome by administering laparoscopic surgery [71]. Chemical tumour ablation (e.g. by ethanol injection) plays no role, since thermal ablation has proven better disease control and outcomes [72]. In very small lesions, superiority of thermal ablation is minimal [73].

High conformal, high dose rate radioablation (stereotactic body radiotherapy; high dose rate brachytherapy)

High conformal high dose rate (HDR) radioablation and stereotactic body radiotherapy (SBRT) may be considered as alternatives for the ablation of tumours with a high risk of local failure after thermal ablation due to location [III, C]. High conformal irradiation techniques with hypofractionated (SBRT) or single fraction dose regimens (HDR brachytherapy) have evolved as alternatives to thermal ablation in recent years. In contrast to classic fractionated irradiation schemes, high conformal HDR irradiation techniques such as SBRT or CT-guided HDR brachytherapy have proven efficacy with tumour control rates > 90% after 12 months in ≤ 5 cm (SBRT) or ≤ 12 cm tumour diameter (HDR brachytherapy) in single-centre studies [74–77]. However, a recent comparative trial has demonstrated better survival when applying RFA than SBRT in small tumours ≤ 3 cm [78]. In contrast to thermal ablation, high conformal HDR radioablation is not limited by adjacency to large vessels, exophytic growth or central location. Both SBRT and HDR brachytherapy have demonstrated excellent safety profiles [79, 80]. External beam radiotherapy (EBRT) can be used to control pain in patients with bone metastases [III, B]. Any ablation recommendation should be proposed by the local multidisciplinary meeting (MDM) based on liver function, tumour size, tumour location and the medical expertise provided by the given treatment centre.

Transarterial therapies

The almost exclusive arterial vascularisation of HCC resulted in the application of intra-arterial infusion of chemotherapy alone (doxorubicin, cisplatin, mytomycin C or combinations), mixed with the contrast agent lipiodol (ethiodised oil) that is selectively retained by HCC nodules, embolising material (e.g. coils, gelatin sponge pieces or polyvinyl alcohol-calibrated particles) or tiny radioactive particles containing yttrium-90 (90Y).

Absolute contraindications for transarterial therapies are decompensated cirrhosis, extensive tumour burden, reduced portal vein flow, renal failure or any technical contraindication to transarterial therapy. Important relative contraindications include bile duct occlusion or incompetent papilla, reduced PS, impaired liver function (Child-Pugh B), high-risk oesophageal varices, portal vein thrombosis of any kind for TACE or involving the main trunk for selective internal radiotherapy (SIRT) [81].

Transarterial chemoembolisation

Overall, the efficacy of TACE has been explored in seven randomised trials compared with best supportive care (BSC) [82]. Only two studies reported a survival benefit for the treatment arm [83, 84]. The benefit of TACE in prolonging OS was demonstrated in selected asymptomatic patients with maintained liver function that belong to the BCLC A stage to early intermediate BCLC B stage, who had a small tumour burden but were not amenable to surgery or local ablation [I, A]. Median OS (mOS) of 30–45 months can be expected in this population [85–87]. Shorter median survival of < 20 months has been reported in real life cohorts when patients with no proven benefit are treated including those in Child-Pugh B stage, with portal vein invasion, large tumour burden or deteriorating liver function under TACE [88–91]. Several scores have been developed to identify patients that benefit from TACE from retrospective cohort studies. Currently, only the hepatoma arterial-embolisation prognostic (HAP) score has been validated in a prospective trial and in multiple large international datasets [92, 93]. The HAP score is able to define four distinct prognostic groups with respect to OS and could be used as a stratification factor for TACE trials in future [88]. Outside clinical trials, the use of therapeutic algorithms based on prognostic scores of unknown predictive values is currently not recommended for the selection of candidates to initial and repeated TACE [III, A].

Conventional lipiodol-based TACE is the standard of practice, although using doxorubicin-eluting bead (DEB)-TACE is an option to minimise systemic side effects of chemotherapy [I, C]. Compared with conventional TACE, in RCTs DEB-TACE is associated with significantly fewer side effects related to the leakage of doxorubicin into the systemic circulation [94] and provides a more standardised way to perform TACE. No prospective trial has so far demonstrated the superiority of conventional TACE, bland embolisation or DEB-TACE. One randomised phase II trial compared cisplatin-based conventional TACE with bland embolisation using polyvinyl alcohol particles alone, and two trials have compared DEB-TACE with bland embolisation using unloaded beads [95–97]. None of these trials showed an apparent clinical benefit in terms of OS for the addition of chemotherapy; non-inferiority was also formally not proven.

The optimal duration and frequency of TACE treatment is not yet defined. TACE should not be repeated if a substantial necrosis is not achieved after the second session, or when a subsequent session fails to induce remission at sites that have initially responded to TACE. Additionally, the indication of TACE should be critically re-evaluated in patients with reduced PS and impaired liver function following TACE treatment.

The combination of TACE with systemic agents such as sorafenib—either sequential or concomitant—is not recommended in clinical practice [I, E]. Five randomised trials with 2468 patients have not shown a clinical meaningful benefit of systemic therapy (sorafenib, brivanib or orantinib) in
combination with or following TACE compared with TACE alone in terms of median objective response rate (mORR), median progression-free survival (mPFS) or mOS [92, 98–101].

**Selective internal radiotherapy**

SIRT is based on the injection of microspheres loaded with the pure beta emitter $^{90}$Y into the hepatic arterial circulation and has no or minimal ischaemic effect. SIRT with $^{90}$Y glass or resin microbeads produces tumour responses and high disease control rates with a safe profile in phase II studies and registries [102].

SIRT is not recommended as first-line therapy for HCC patients in intermediate and advanced stage [I, E]. Two recent phase III trials randomised patients free from extrahepatic metastasis and with preserved liver function to sorafenib or SIRT using resin microspheres. The SARAH trial in France ($n = 459$ patients) and the SIRveNIB trial in Asia-Pacific (360 patients) failed to meet the primary endpoint of improved OS compared with sorafenib; survival for the sorafenib arm ranged from 10.2 to 9.9 months compared with 8.8 to 8 months for $^{90}$Y [hazard ratio (HR) 1.12–1.15] [103, 104]. The applicability of $^{90}$Y was limited to 72%–77% of patients due to treatment contraindications. Also, the per-protocol subgroup analyses did not yield any survival advantages. The SORAMIC phase II trial additionally analysed whether the addition of SIRT to sorafenib improves OS in patients with advanced HCC. However, this study failed to meet the primary endpoint, and the addition of SIRT to sorafenib did not show an OS that was superior to sorafenib alone. Whether subgroups such as non-cirrhotic patients or non-alcoholic aetiology of the cirrhosis with high positive HR for SIRT addition to sorafenib hold promise must be further validated [105].

In the phase III studies, SIRT was associated with higher response rates, delayed tumour progression in the liver and fewer adverse events (AEs) compared with sorafenib. The observed delay in tumour progression was also observed in retrospective cohort studies with survival rates comparable to those reported for TACE and sorafenib [106–108]. Thus, in exceptional circumstances, for patients with liver-confined disease and preserved liver function in whom neither TACE nor systemic therapy is possible, SIRT may be considered. Additionally, SIRT may be considered instead of TACE for the treatment of small tumours in patients waiting for liver transplantation, in an attempt to avoid drop-out from the list due to tumour progression [106].

**Management of advanced disease**

During the past 40 years, numerous RCTs testing treatments for advanced HCC have been published [109]. Sorafenib showed a survival benefit and it was established as the sole systemic treatment for patients with advanced HCC or those progressing from locoregional therapies. More recently, five additional drugs have shown positive clinical results in first- and second-line settings (see Figure 1).

**Systemic therapies for advanced HCC**

**Chemotherapy.** Chemotherapy has not been shown to improve survival in randomised trials and is not recommended as a standard of care [II, C].

To date, four trials have been reported for which the experimental arms were: PIAF (cisplatin/interferon/doxorubicin/fluorouracil), the tubulin binding agent T138067, nolatrexed and FOLFFOX (leucovorin/fluorouracil/oxaliplatin) [110–112]. None improved survival compared with doxorubicin, although response rates were higher with FOLFFOX (8.2% versus 2.7%, $P = 0.0233$) and a small benefit in median survival was also seen on long-term follow up (6.4 versus 5.0 months, $P = 0.0425$). One trial has compared sorafenib with the combination of sorafenib and doxorubicin but did not demonstrate improved survival with combination therapy [113]. In summary, the clinical benefit of chemotherapy in the management of HCC has not been established.

**Targeted first-line therapies.** Sorafenib is the standard of care for patients with advanced HCC and those with intermediate-stage (BCLC B) disease not eligible for, or progressing despite, locoregional therapies. It is recommended in patients with well-preserved liver function and Eastern Cooperative Oncology Group (ECOG) PS 0–2 [I, A].

Lenvatinib showed non-inferiority efficacy compared with sorafenib and can be considered in patients with advanced HCC without main portal vein invasion and with ECOG PS 0–1 as a front-line systemic treatment, pending European Medicines Agency (EMA) approval [I, A].

**Sorafenib:** Sorafenib, a multikinase inhibitor blocking 40 kinases including vascular endothelial growth factor receptor 2 (VEGFR2) and BRAF, was established as the standard systemic therapy for HCC according to all international guidelines following the results reported a decade ago. It is indicated for patients with well-preserved liver function (Child-Pugh A class) and with advanced tumours (BCLC C) or those tumours at intermediate stage (BCLC B) progressing upon locoregional therapies. In the SHARP phase III trial, sorafenib improved survival compared with placebo (HR 0.69; $P = 0.001$; 7.9–10.7 months) [114]. The target population of this trial was mostly patients with advanced HCC (80%, including 35% with macrovascular invasion and 50% with extrahepatic spread). The results of the SHARP trial were subsequently confirmed in the Asia-Pacific phase III trial [115] and in 10 subsequent trials with an mOS in the range of 10–12 months. Objective responses are uncommon; 2% by Response Evaluation Criteria in Solid Tumours (RECIST) and ~10% by modified RECIST (mRECIST) [116]. A recent meta-analysis of individual data of two RCTs testing sorafenib has shown that, although of benefit to all patients across the board, it provides better outcomes in patients with HCV-related HCC and those with liver-only disease [117]. No predictive biomarkers of responsiveness to sorafenib have been identified.

The recommended daily dose of sorafenib is 800 mg. Median treatment duration is estimated to be 5–6 months, but early prevention of toxicities can enhance tolerability. Treatment is associated with manageable AEs, such as diarrhoea, hand–foot skin reactions, fatigue and hypertension. Around 15% of patients are intolerant to sorafenib, and thus treatment needs to be withdrawn, while another 35% of patients require dose reduction. Treatment-related liver failure or life-threatening complications are marginal. Considering the restrictive indication of sorafenib in terms of liver failure (mostly Child-Pugh A class), it has been estimated that only
half of patients at advanced stages can be suitable for this treatment. Clinically symptomatic vascular disease—either coronary or peripheral—is considered a formal contraindication.

**Lenvatinib:** Several phase III trials have been conducted to challenge sorafenib in front line (testing sunitinib, brivanib, erlotinib, linifanib or doxorubicin), but lenvatinib has only recently challenged sorafenib in front line (testing sunitinib, brivanib, erlotinib). Lenvatinib is an oral multikinase inhibitor that targets VEGFR1–3 and fibroblast growth factor receptor (FGFR)1–4, among others. Lenvatinib demonstrated non-inferiority results compared with sorafenib in an open-label, phase III, multicentre, non-inferiority trial involving patients with advanced HCC (excluding main portal vein invasion, clear bile duct invasion and > 50% of tumour to total liver volume occupancy). The dose was adjusted to body weight. The study met its primary endpoint of non-inferiority in OS [HR 0.92; 95% confidence interval (CI) 0.79–1.06; mOS lenvatinib, 13.6 months versus sorafenib, 12.3 months]. Secondary endpoints such as PFS, time to progression and ORR (24% versus 9.2% for sorafenib, mRECIST ORR) were significantly better for lenvatinib. Lenvatinib-related most common any-grade AEs compared with sorafenib were as follows: hypertension (42% versus 30%), diarrhoea (39% versus 45%) and hand–foot skin reaction (27% versus 52%). Median time on lenvatinib was 5.7 months. Time to worsening in quality of life was similar in both treatment arms (HR 1.01). These results position lenvatinib as an option in first-line treatment for advanced HCC, once the drug is approved by regulatory agencies. No cost-effectiveness studies comparing both drugs are available.

**Targeted second-line therapies.** Regorafenib is the standard of care for patients with advanced HCC who have tolerated sorafenib but progressed. It is recommended in patients with well-preserved liver function and ECOG PS 0–1 [1, A].

Cabozantinib can be considered for patients who had progressive disease on one or two systemic therapies with well-preserved liver function and ECOG PS 0–1, pending EMA approval [1, A].

Ramucirumab (RAM) can be considered for patients in second-line treatment with baseline AFP ≥ 400 ng/mL, well-preserved liver function and ECOG PS 0–1, pending EMA approval [1, A].

**Regorafenib:** Recently, a phase III study comparing regorafenib (a multikinase inhibitor targeting similar kinases as sorafenib) with placebo in patients progressing despite sorafenib has reported a benefit in survival (HR 0.62; P < 0.0001, mOS 7.8–10.6 months) [119]. Treatment improved survival in all subgroups of patients. In this trial, 88% of patients were BCLC C and 12% BCLC B, with all of them tolerant to but progressing on sorafenib. Around 30% of patients presented with macrovascular invasion; 70% with extrahepatic spread and 45% with AFP > 400 ng/dL. The response rate was 10%, based upon mRECIST. Treatment was started at 160 mg/day (3 weeks on/1 week off). Median time on treatment was 3.5 months. AEIs led to 51% dose reductions and 10% treatment discontinuation. Approval of regorafenib as a standard of care opens the field for third-line therapies. It should be kept in mind, however, that most patients at BCLC B-C stages not candidates to standard-of-care therapies (TACE, sorafenib, regorafenib) are generally unsuitable candidates to enter into clinical trials.

These patients along with those at BCLC D stage should receive best supportive/palliative care, including management of pain, nutrition and psychological support.

**Cabozantinib:** Cabozantinib is a MET, VEGFR2, AXL and RET inhibitor approved for thyroid and renal cancer. The CELESTIAL trial, a randomised, global phase III trial, examined cabozantinib versus placebo in patients with advanced HCC who had been previously treated with sorafenib [120]. In contrast to regorafenib, this trial allowed the inclusion of patients that were intolerant to sorafenib and who had progressive disease on one or two systemic therapies. In this trial, 30% of patients presented with macrovascular invasion, 78% with extrahepatic spread and 42% with AFP > 400 ng/dL. Treatment was started at 60 mg/day, and median time on treatment was 3.8 months. OS results favoured cabozantinib compared with placebo (HR 0.76, 95% CI 0.63–0.92; P = 0.0049; mOS 10.2 versus 8.0 months). Response rate was 4% with cabozantinib based upon RECIST v1.1. The most common grade 3/4 AEs with cabozantinib versus placebo were palmar-plantar erythrodysesthesia (17% versus 0%), hypertension (16% versus 2%), increased aspartate aminotransferase (AST) (12% versus 7%), fatigue (10% versus 4%) and diarrhoea (10% versus 2%) and led to 62% dose reductions and 16% treatment discontinuation.

**Ramucirumab:** RAM is a human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that inhibits ligand activation of VEGFR2. In the phase III REACH trial mOS in the overall population was not statistically significant, but a meaningful improvement was observed in a patient subgroup with baseline AFP ≥ 400 ng/mL. Based on these data, the REACH-2 phase III trial analysed the efficacy of RAM in patients with elevated baseline AFP following therapy with sorafenib. RAM treatment significantly improved mOS from 7.3 to 8.5 months (HR 0.710; 95% CI 0.531, 0.949; P = 0.0199) and mPFS from 1.6 to 2.8 months (HR 0.452; 95% CI 0.339, 0.603; P < 0.0001) compared with placebo [121]. ORR was 4.6% with RAM versus 1.1% with placebo (P = 0.1156) and ORR was 59.9% RAM versus 38.9% with placebo (P = 0.0006). The safety profile observed in the REACH-2 study was consistent with what has been previously observed, and the only grade ≥ 3 AEs occurring at a rate of ≥ 5% in the RAM arm were hypertension (12.2% versus 5.3%) and hyponatremia (5.6% versus 0%).

**Immunotherapies**

Immunotherapy with nivolumab and pembrolizumab can be considered in patients who are intolerant to, or have progressed under, approved tyrosine kinase inhibitors, pending EMA approval [III, B]. For a definitive recommendation, it is necessary to wait for the results of randomised trials.

To date, the most promising immunotherapeutic approach has been the use of immune checkpoint inhibitors. Initial results from a small single-arm phase II trial of tremelimumab [a fully humanised IgG2 anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody] demonstrated a response rate of 17% and time to progression of 6.5 months [122]. More recently, a large single-arm phase I/II trial of the fully human IgG4 programmed cell death protein 1 (PD-1) inhibitor nivolumab (CheckMate 040), has been reported [123]. A total of 262 patients were treated of which 48
were in dose escalation and 214 in dose expansion. The dose of 3 mg/kg every 2 weeks was shown to be tolerable during dose escalation and was used in dose expansion (in which patients were required to be Child-Pugh A and ECOG PS $\leq 1$). In dose expansion, there were no treatment-related deaths and grade 3/4 AST and alanine aminotransferase (ALT) increase occurred in 4% and 2%, respectively. The most common AEs of any grade were fatigue (23%), pruritus (21%) and rash (15%). The ORR was 20% (RECIST v1.1) and the PFS and 9-month OS were 4.0 months and 74%, respectively. Expression of programmed death-ligand 1 (PD-L1) on tumour cell membranes was not found to be predictive. Overall, 145 patients in the expansion cohort had received prior sorafenib and, after extended follow-up, the mOS was 15.6 months (13.2–18.9). This compares favourably with all of the previously reported phase III second-line trials in HCC, for which mOS has been between 7.6 and 10.6 months in the experimental arm. On this basis, the United States Food and Drug Administration (FDA) granted accelerated approval for the use of nivolumab in patients previously treated with sorafenib, on the condition that further trials were required to verify the clinical benefit of nivolumab in patients with HCC. The first-line phase III trial comparing sorafenib with nivolumab, CheckMate 459, is expected to report in 2018 and, if positive, will position nivolumab as a first-line treatment option.

Meanwhile, a phase II trial of the anti-PD-1 antibody pembrolizumab as second-line treatment (KEYNOTE-224) has recently been reported. The 16.3% response rate (RECIST v1.1) and 78% 6-month OS observed among the 104 patients included is in line with the results seen with nivolumab. Median time to progression was 4.9 months (95% CI: 3.9–8.0), mPFS was 4.9 months (95% CI 3.4–7.2) and mOS was 12.9 months (95% CI 9.7–15.5) [124]. However, we recommend obtaining tissue in all research studies for exploring biomarkers of response.

There has been increasing interest in stratified trials driven by predictive biomarkers, and a number of earlier phase trials are exploring this strategy in HCC. Investigations into the molecular pathology of HCC have identified recurrent mutations of which the most common are in the TERT promoter, CTNNB1, TP53 and epigenetic regulators including ARID1A and ARID2 [125]. While these pathways provide a challenge for drug development, less common molecular aberrations are tractable and show promise. For example, overexpression of FGF19 is found in $\leq 20%$ of HCCs, and several compounds directed against its receptor FGFR4 are in development, including BLU-554 and FGF401. Despite the disappointing results of the tivantinib phase III trial [126], there are ongoing studies enriching for MET pathway activation or MET overexpression with INC280 and MSC2156119J. Activation of the transforming growth factor beta 1 (TGFβ1) pathway is associated with a more aggressive subclass of HCC and is being targeted with galunisertib in combinations with sorafenib and nivolumab, although these trials are not currently enrolled for pathway activation. Numerous other targets are being evaluated including androgen receptor, signal transducer and activator of transcription 3 (STAT3) inhibitor, histone deacetylase inhibitor (HDACi) and cyclin-dependent kinase 4/6 (CDK 4/6), but, while personalised therapy holds promise for the future, there is insufficient evidence for molecular stratification at the present time.

### Follow-up, long-term implications and survivorship

Many HCC treatments act by induction of tumour necrosis or reduction in vascularity, which is not necessarily accompanied by tumour shrinkage. Viable tumour should be assessed using dynamic CT or MRI studies and should be defined as uptake of contrast agent in the arterial phase [III, A]. mRECIST are recommended for assessment of response/progression to locoregional treatments.

**Table 5. Response assessment by RECIST v1.1 and mRECIST for HCC**

<table>
<thead>
<tr>
<th>RECIST</th>
<th>mRECIST</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>Disappearance of all target lesions</td>
</tr>
<tr>
<td>PR</td>
<td>At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions</td>
</tr>
<tr>
<td>SD</td>
<td>Any cases that do not qualify for either partial response or PD</td>
</tr>
<tr>
<td>PD</td>
<td>An increase of at least 20% in the sum of the diameters of target lesions (lymph nodes of 1.5 cm diameter), taking as reference the smallest sum of the diameters of target lesions recorded since treatment started</td>
</tr>
</tbody>
</table>


### Ongoing research in personalised therapy for HCC

Molecular profiling is not recommended as standard of practice since it currently has no direct implication for decision making.
Thermal ablation by means of RFA or MWA may be recommended as first-line treatment in very early-stage disease (BCLC 0) [II, A]

Adjuvant therapy is not recommended for HCC patients after OLT, LR or local ablation [I, E]

In the case of a long-anticipated waiting time (if amenable) direct resection of the lesion may be considered according to tumour size [IV, B]

Histopathological diagnosis of tumours biopsies relies on standard (H&E) and special stains (e.g. reticulin), and—if required—IHC

Further immunohistochemical markers have been shown to improve the diagnosis of highly differentiated HCC, including glutamine synthetase, glypican 3, CTC, EZH2 and HSP70 [IV, B]

A combination of the three markers glutamine synthetase, glypican 3 and HSP70 has been consented as a diagnostic panel (2/3 marker positivity has 70% sensitivity and 100% specificity for HCC) and the use of further markers seems to increase the sensitivity [IV, B]

Staging and risk assessment

Staging of HCC is important to determine outcome and planning of optimal therapy and includes assessment of tumour extent, AFP level, liver function, portal pressure and clinical PS [III, A]

BCLC is the commonly accepted staging system for prognostic prediction and treatment allocation

There is no demonstrated clinical benefit of carrying out an FDG-PET scan as a staging modality, despite some evidence that there is a correlation of higher FDG uptake with poor differentiation, tumour size, serum AFP levels and microvascular invasion [IV, D]

Liver function is classically assessed by the Child-Pugh scoring system (serum bilirubin, serum albumin, ascites, prothrombin time and hepatic encephalopathy) [III, A]

Within the Child-Pugh A group, measurement of the ALBI score is able to split that group into best prognosis (ALBI 1) and lesser prognosis (ALBI 2), with median survivals of 26 versus 14 months, respectively [IV, B]

The finding of oesophageal varices and/or splenomegaly with blood platelet counts of 100 \times 10^9 cells/L suggests clinically important portal hypertension, which can also be measured invasively by the transjugular route (hepatic-venous pressure gradient > 10 mmHg) [III, A]

Management of early and intermediate HCC

Child-Pugh A patients without immanent portal hypertension are considered good candidates for minor/major LRIs [III, B]

Carefully selected patients with Child-Pugh B and/or portal hypertension may be candidates for minor surgical resection [III, A]

LR in cirrhosis should preferably be carried out as laparoscopic resection [IV, A]

The Milan criteria (one lesion < 5 cm; alternatively, up to three lesions, each < 3 cm; no extrahepatic manifestations; no evidence of microvascular invasion) are currently the benchmark for the selection of patients with HCC for OLT. OLT is recommended for patients that fit the Milan criteria, for which < 10% recurrence and 70% 5-year survival are expected [II, A]

Among several more liberal proposals (up-to-seven, Toronto criteria, UCSF), only the UCSF criteria (one tumour < 6.5 cm, three nodules at most with the largest < 4.5 cm, and total tumour diameter < 8 cm) were prospectively validated and showed similar outcome and, as such, may also be considered for OLT in patients with HCC beyond Milan criteria [III, B]

In the case of a long-anticipated waiting time (> 3 months), patients may be offered resection, local ablation or TACE in order to minimise the risk of tumour progression and to offer a ‘bridge’ to transplant [III, B]

Adjuvant therapy is not recommended for HCC patients after OLT, LR or local ablation [I, E]

Thermal ablation by means of RFA or MWA may be recommended as first-line treatment in very early-stage disease (BCLC 0) [II, A]
therapies [III, B]. RECIST were primarily designed for the evaluation of cytotoxic agents. Modifications of RECIST (mRECIST) are available and are based on the measurement of the diameter of the viable tumour component of target lesions (Table 5) [116]. mRECIST also include guidelines regarding evaluation of vascular invasion, lymph nodes, effusions and new lesions. In 2011, the first study reported a link between mRECIST, EASL (European Association for the Study of Liver) criteria and OS in patients treated with TACE in contrast to RECIST v1.1, which was subsequently confirmed and validated [127–130]. In contrast to locoregional therapies, the value of mRECIST in the evaluation of systemic therapy in HCC is not yet established. mRECIST were prospectively evaluated in the BRISK trial and responders had a better OS compared with non-responders [131]; however, a higher objective response by mRECIST does not correlate with an improved OS in subsequent phase III trials [118]. In addition, the prospective comparison between mRECIST and RECIST in two trials with nintedanib and one trial with regorafenib revealed a very similar outcome, with no clear advantage of mRECIST [119, 132]. Overall, mRECIST need further prospective validation but may be used in daily clinical practice to consider not only tumour diameters but also lesion viability in therapy decision making [III, B].

Follow-up of patients who underwent radical treatments (resection or RFA) should consist of the clinical evaluation of liver decompensation and the early detection of recurrence by dynamic CT or MRI studies every 3 months during the first 2 years and surveillance every 6 months thereafter [III, A]. Patients with more advanced stages of HCC who are treated with TACE or systemic agents are evaluated clinically for signs of liver decompensation and for tumour progression by dynamic CT or MRI every 3 months to guide therapy decisions [III, B].

Standard of care for patients with advanced HCC and those with intermediate-stage (BCLC B) disease not eligible for, or progressing despite, locoregional therapies. It is recommended in patients with well-preserved liver function and ECOG PS 0–2 [I, A]. Lenvatinib showed non-inferiority efficacy compared with sorafenib, and can be considered as first-line therapy in patients with advanced HCC without main portal vein invasion, clear bile duct invasion and ≥ 50% of tumour to total liver volume occupancy, pending EMA approval [I, A].

Regorafenib is the standard of care for patients with advanced HCC who have tolerated sorafenib but progressed. It is recommended in patients with well-preserved liver function and ECOG PS 0–1 [I, A]. Cabozantinib can be considered for patients who had progressive disease on one or two systemic therapies with well-preserved liver function and ECOG PS 0–1, pending EMA approval [I, A]. Ramucirumab can be considered for patients in second-line patients with baseline AFP > 400 ng/mL, well-preserved liver function and ECOG PS 0–1, pending EMA approval [I, A]. Immunotherapy with nivolumab and pembrolizumab can be considered in patients who are intolerant to, or have progressed under, approved tyrosine kinase inhibitors, pending EMA approval [III, B]. For a definitive recommendation, it is necessary to wait for the results of randomised trials.

Follow-up, long-term implications and survivorship

• Viable tumour should be assessed using dynamic CT or MRI studies and be defined as uptake of contrast agent in the arterial phase [III, A].
• mRECIST need further prospective validation but may be recommended in daily clinical practice to consider not only tumour diameters but also lesion viability in therapy decision making [III, B].
• mRECIST are recommended for assessment of response/progression to locoregional therapies [III, B].
• There is limited evidence that OS can be predicted more accurately by mRECIST than RECIST v1.1 [IV, B].
• Follow-up of patients who underwent radical treatments (resection or RFA) should consist of the clinical evaluation of liver decompensation and the early detection of recurrence by dynamic CT or MRI studies every 3 months during the first 2 years and surveillance every 6 months thereafter [III, A].
• Patients with more advanced stages of HCC who are treated with TACE or systemic agents are evaluated clinically for signs of liver decompensation and for tumour progression by dynamic CT or MRI every 3 months to guide therapy decisions [III, A].

AFP, alpha foetoprotein; ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; CC, cholangiocarcinoma; CEUS, contrast-enhanced ultrasound; CK19, cytokeratin 19; CT, computed tomography; DEB, doxorubicin-eluting bead; EASL, Eastern Cooperative Oncology Group; EMA, European Medicines Agency; EZH2, enhancer of zeste homologue 2; FDG, fluorodeoxyglucose; H&E, haematoxylin and eosin; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HCR, high dose rate; HSP70, heat shock protein 70; IHC, immunohistochemistry; LR, liver resection; mRECIST, modified Response Criteria in Solid Tumours; MRI, magnetic resonance imaging; MWA, microwave ablation; OLT, orthotopic liver transplantation; OS, overall survival; PET, positron emission tomography; PS, performance status; RECIST, Response Criteria in Solid Tumours; RFA, radiofrequency ablation; SBRT, stereotactic body radiotherapy; SIRT, selective internal radiotherapy; TACE, trans-arterial chemoembolisation; UCSF, University of California San Francisco; US, ultrasound.
MRI every 3 months to guide therapy decisions [III, A].

Compensation and for tumour progression by dynamic CT or agents (e.g. sorafenib) are evaluated clinically for signs of liver decompensation and the early detection of recurrence by dynamic CT or MRI studies every 3 months during the first year and surveillance every 6 months thereafter [III, A] [66, 137, 138]. Patients with recurrence following radical therapies may still be candidates for curative therapies. Patients with more advanced stages of HCC who are treated with TACE or systemic treatments (resection or RFA) should consist of the clinical evaluation of liver decompensation and for tumour progression by dynamic CT or MRI every 3 months to guide therapy decisions [III, A].

In summary, follow-up of patients who underwent radical treatments (resection or RFA) should consist of the clinical evaluation of liver decompensation and the early detection of recurrence by dynamic CT or MRI studies every 3 months during the first year and surveillance every 6 months thereafter [III, A] [66, 137, 138]. Patients with recurrence following radical therapies may still be candidates for curative therapies. Patients with more advanced stages of HCC who are treated with TACE or systemic agents (e.g. sorafenib) are evaluated clinically for signs of liver decompensation and for tumour progression by dynamic CT or MRI every 3 months to guide therapy decisions [III, A].

In the context of immunotherapy, response evaluation may also be very challenging as pseudoprogression (transient increase in tumour size and AFP, followed by response) has been described also in HCC [135]. Recent trials with immunotherapies reported response rates of up to 25% by RECIST v1.1, and mRECIST have not been validated in this setting. Serum tumour markers (such as AFP levels) may be helpful particularly in the case of not easily measurable disease but should not be used as the only determinant for treatment decisions [IV, B]. Pseudoprogression is incredibly rare but, in the future, immune RECIST (iRECIST) should be discussed in this context [136].

In summary, follow-up of patients who underwent radical treatments (resection or RFA) should consist of the clinical evaluation of liver decompensation and the early detection of recurrence by dynamic CT or MRI studies every 3 months during the first year and surveillance every 6 months thereafter [III, A] [66, 137, 138]. Patients with recurrence following radical therapies may still be candidates for curative therapies. Patients with more advanced stages of HCC who are treated with TACE or systemic agents (e.g. sorafenib) are evaluated clinically for signs of liver decompensation and for tumour progression by dynamic CT or MRI every 3 months to guide therapy decisions [III, A].

**Methodology**

These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines [ESMO-Guidelines-Methodology]. The relevant literature has been selected by the expert authors. A summary of recommendations is shown in Table 6. Levels of evidence and grades of recommendation have been applied using the system shown in Table 7. Statements without grading were considered justified standard clinical practice by the experts and the ESMO Faculty. This manuscript has been subjected to an anonymous peer review process.

**Disclosure**

AV has received honoraria for talks and advisory boards from Bayer, Roche, Lilly, Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Eisai, Novartis and Ipsen; AC has provided consulting and advisory services for Merck Serono, Amgen, Servier, Roche, Lilly, Novartis, Takeda and Astellas and has received research support from Roche, Merck Serono, Servier, Beigene and Astellas; IC has reported being a member of the advisory boards of Eli-Lilly, Bristol-Myers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics and AstraZeneca and has received research funding from Eli-Lilly, Janssen-Cilag, Sanofi Oncology, Merck-Serono and honorarium from Eli-Lilly; BD has received honoraria or consultation fees from Bayer, Bristol-Myers Squibb, MSD, Merck KGAa, Ipsen, Eisai and Lilly; JR has received consulting fees from Bayer, Bristol-Myers Squibb, Incyte, Lilly, Eisai, Celsion, Glycotest, Ipsen, Merck and Exelixis and research support from Incyte, Bayer, Bristol-Myers Squibb and Eisai; TM has received consulting fees from Bristol-Myers Squibb, Bayer, Eisai, Ipsen, Merck, BTG and Beigene; UN has given presentations for Merck, Amgen, Roche,Grünenthal and Bayer on topics other than HCC; JR has received consulting fees and research grants from Bayer Healthcare and Sirtex Medical; BS has received consulting and/or lecture fees from Adaptimmune, AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Onxeo, Sirtex and Terumo; PS has reported being a member of advisory board and has received grants from Novartis and

**Table 7. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System*)

<table>
<thead>
<tr>
<th>Levels of evidence</th>
<th>Grades of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I Strong evidence for efficacy with a substantial clinical benefit, strongly recommended</td>
<td></td>
</tr>
<tr>
<td>II Strong or moderate evidence for efficacy with a limited clinical benefit, generally recommended</td>
<td></td>
</tr>
<tr>
<td>III Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (AEs, costs, ...), optional</td>
<td></td>
</tr>
<tr>
<td>IV Moderate evidence against efficacy or for adverse outcome, generally not recommended</td>
<td></td>
</tr>
<tr>
<td>V Strong evidence against efficacy or for adverse outcome, never recommended</td>
<td></td>
</tr>
</tbody>
</table>

*By permission of the Infectious Diseases Society of America [139].
References


42. Fuks D, Cauchy F, Fusco G et al. Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. J Hepatol 2014; 61: 589–593.


120. Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. J Clin Oncol 2018; 36(Suppl 4): 207.


